SCHEMBL3883607

SCHEMBL3883607

CN(C)S(=O)(=O)c1ccc2cc(-c3cc(CCC(=O)O)ccc3OCC3CCCC3)ccc2c1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 5/20 0.43
THRA P10827 1/20 0.42
THRB P10828 1/20 0.42
S1PR1 P21453 1/20 0.41
BRD4 O60885 2/20 0.40
CTSD P07339 2/20 0.40
LMNA P02545 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.39
ALDH1A1 P00352 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PDE4D Q08499 1/20 0.38
MEN1 O00255 1/20 0.38
RECQL P46063 1/20 0.38
KMT2A Q03164 1/20 0.38
PTGES O14684 1/20 0.37
ALOX5 P09917 1/20 0.37
RORC P51449 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3884610 0.91 ALDH1A1 (0.43) BRD4CTSDLMNAALDH1A1L3MBTL1
SCHEMBL3883323 0.90 BRD4 (0.48) FFAR4THRATHRBS1PR1BRD4
SCHEMBL3881619 0.88 THRA (0.47) FFAR4THRATHRBS1PR1BRD4
SCHEMBL3881625 0.88 FFAR4 (0.43) FFAR4THRATHRBS1PR1BRD4
SCHEMBL3690662 0.87 FFAR4 (0.41) FFAR4THRATHRBS1PR1MEN1
SCHEMBL3884083 0.86 RORC (0.39) BRD4PTGDR2ALDH1A1L3MBTL1RORC
SCHEMBL3883134 0.85 FFAR4 (0.46) FFAR4THRATHRBS1PR1
SCHEMBL3682868 0.84 FFAR4 (0.43) FFAR4THRATHRBS1PR1BRD4
SCHEMBL3883274 0.84 FFAR4 (0.55) FFAR4THRATHRBS1PR1
SCHEMBL3883780 0.84 FFAR4 (0.46) FFAR4THRATHRBS1PR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP claimed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US claimed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP claimed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US claimed
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP disclosed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US disclosed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP disclosed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof PTGER1, CYSLTR1, PTGS1 FFAR4 115/4885THRA 1720/4885THRB 3187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.